Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 351 to 400 of 2490 results for term

  1. Fetal monitoring in labour (NG229)

    This guideline covers methods for monitoring the wellbeing of the baby during labour. It includes risk assessment to determine the appropriate level of fetal monitoring, using clinical assessment in addition to fetal monitoring, and interpreting and acting on monitoring findings.

    NICE guideline
    Last updated
    12 November 2025
    View recommendations

    Sections for NG229

  2. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA763

  3. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    30 September 2020
    View recommendations

    Sections for TA650

  4. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  5. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

    Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

    Technology appraisal guidance
    Published
    8 October 2025
    View recommendations

    Sections for TA1101

  6. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

    Quality standard
    Published
    11 May 2018
    View quality statements

    Sections for QS167

  7. Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA508)

    Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.

    Technology appraisal guidance
    Published
    7 March 2018
    View recommendations

    Sections for TA508

  8. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    28 March 2024
    View recommendations

    Sections for TA962

  9. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up? Any explanatory notes(if applicable) Why the...

    Research recommendation
    Published
    25 October 2019

  10. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

    Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.

    Technology appraisal guidance
    Published
    27 March 2013
    View recommendations

    Sections for TA276

  11. Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes?

    replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes? Any explanatory...

    Research recommendation
    Published
    16 December 2021

  12. Individual-level interventions: What is the long-term effectiveness and cost effectiveness of universal individual-level interventions on mental wellbeing in different types of organisations?

    NG212/01 Question Individual-level interventions: What is the long-term effectiveness and cost effectiveness of universal...

    Research recommendation
    Published
    8 April 2022

  13. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA958

  14. Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

    Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA832

  15. The physical health benefits of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks?

    of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication...

    Research recommendation
    Published
    9 June 2015

  16. Is a group-based parent training intervention for parents or carers of autistic children and young people clinically and cost effective in reducing early and emerging behaviour that challenges in the short- and medium-term compared with treatment as usual?

    reducing early and emerging behaviour that challenges in the short- and medium-term compared with treatment as usual? Any explanatory...

    Research recommendation
    Published
    10 August 2021

  17. Indwelling urinary catheters: catheter selection:- For patients using a long-term indwelling urinary catheter, what is the clinical and cost effectiveness of impregnated versus hydrophilic versus silicone catheters in reducing symptomatic urinary tract infections, encrustations and/or blockages?

    Indwelling urinary catheters: catheter selection:- For patients using a long-term indwelling urinary catheter, what is the clinical and...

    Research recommendation
    Published
    9 June 2015

  18. Flu vaccination: increasing uptake (QS190)

    This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    9 January 2020
    View quality statements

    Sections for QS190

  19. Multiple sclerosis (QS108)

    This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    14 January 2016
    View quality statements

    Sections for QS108

  20. Supporting adult carers (QS200)

    This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 March 2021
    View quality statements

    Sections for QS200

  21. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

    Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.

    Technology appraisal guidance
    Published
    25 November 2020
    View recommendations

    Sections for TA660

  22. Further research, ideally in the form of randomised controlled trials, on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia should report details of patient selection (including prostate size and the amount of median lobe enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and outcome measures of sexual function using established methods.

    enlargement), improvement in lower urinary tract symptoms in the short term and long term, re-intervention rates, and...

    Research recommendation
    Published
    18 February 2019

  23. Further research into arthroscopic radiofrequency chondroplasty of the knee should clearly document patient selection and the types of chondral defects being treated. More evidence on long-term outcomes would be useful.

    selection and the types of chondral defects being treated. More evidence on long-term outcomes would be useful. Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  24. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

    Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA462

  25. NICE encourages further research on laparoscopic gastric plication for severe obesity, which should include information about long-term efficacy and safety, and specifically how the procedure influences further gastric surgery. Comparison with alternative procedures would be useful.

    plication for severe obesity, which should include information about long-term efficacy and safety, and specifically how the procedure...

    Research recommendation
    Published
    9 June 2015

  26. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    1 October 2013

  27. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

    Technology appraisal guidance
    Last updated
    9 October 2025
    View recommendations

    Sections for TA1074

  28. Hip fracture in adults (QS16)

    This quality standard covers diagnosing and managing hip fracture in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    6 January 2023
    View quality statements

    Sections for QS16

  29. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  30. Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)

    Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    3 December 2025
    View recommendations

    Sections for TA1114

  31. Evidence on the safety of genicular artery embolisation for pain from knee osteoarthritis shows no major safety concerns in the short term. Evidence on its efficacy and long-term safety is inadequate in quality and quantity. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page. Research should preferably be randomised controlled trials against sham and current best practice. It should report details of patient selection and identify those who would most benefit from this procedure. It should also report details of the technique used, long-term safety, and patient-reported outcomes. The procedure should only be done by interventional radiologists with specific training in this technique.

    osteoarthritis shows no major safety concerns in the short term. Evidence on its efficacy and long-term safety is...

    Research recommendation
    Published
    5 November 2021

  32. How effective and cost effective are lifestyle weight management programmes available in the UK over at least at least 3 to 5 years, and ideally beyond 10 years. Specifically: - Do short-term (12-week) interventions provide adults with the self-management skills they need to maintain weight loss in the long term? - Are alternative approaches to weight management (such as approaches that focus on a healthy lifestyle, behaviour change and the prevention of weight gain rather than weight loss) effective and cost effective in the long term? - How effective and cost effective are programmes for people of different ages, gender, sexuality or from different ethnic or socioeconomic groups? - How effective and cost effective are programmes for specific population groups, such as adults with depression or with disabilities?

    Specifically: - Do short-term (12-week) interventions provide adults with the self-management skills they need to maintain weight loss...

    Research recommendation
    Published
    9 June 2015

  33. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

    Highly specialised technologies guidance
    Published
    21 October 2020
    View recommendations

    Sections for HST13

  34. COPD: oxygen saturation recording (IND212)

    This indicator covers the percentage of patients with very severe chronic obstructive pulmonary disease (COPD) with a record of oxygen saturation value within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM194

    General practice indicators suitable for use in QOF
    Published
    31 August 2019

  35. Impact of COVID-19: What is the medium-to long-term impact of the COVID-19 pandemic on children and young people's social, emotional and mental wellbeing?

    NG223/11 Question Impact of COVID-19: What is the medium-to long-term impact of the COVID-19 pandemic on children and young people's...

    Research recommendation
    Published
    4 August 2022

  36. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis, including where fertility is a priority. It aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis and the range of treatments available.

    NICE guideline
    Last updated
    11 November 2024
    View recommendations

    Sections for NG73

  37. Self-monitoring strategies:- Does earlier detection of the incidence of late AMD (wet active) by self-monitoring in people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes?

    indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes? Any explanatory notes(if applicable) Why...

    Research recommendation
    Published
    13 November 2018

  38. Supervised exercise programmes for treating people with intermittent claudication:- What is the clinical and cost effectiveness of supervised exercise programmes compared with unsupervised exercise for treating people with intermittent claudication, taking into account the effects on long-term outcomes and continuing levels of exercise?

    people with intermittent claudication, taking into account the effects on long-term outcomes and continuing levels of exercise? Any...

    Research recommendation
    Published
    9 June 2015

  39. Avalglucosidase alfa for treating Pompe disease (TA821)

    Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.

    Technology appraisal guidance
    Published
    24 August 2022
    View recommendations

    Sections for TA821

  40. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA854

  41. UroShield for preventing catheter-associated urinary tract infections (HTG620)

    Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.

    HealthTech guidance
    Published
    31 March 2022
    View recommendations

    Sections for HTG620

  42. Social, emotional and mental wellbeing in primary and secondary education (NG223)

    This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.

    NICE guideline
    Published
    6 July 2022
    View recommendations

    Sections for NG223

  43. NICE encourages further research on transcranial magnetic stimulation (TMS) for treating and preventing migraine. Data should be collected for all patients not entered into controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient selection and the dose and frequency of use. Outcome measures should include the number and severity of migraine episodes, and quality of life in both the short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer term after starting treatment should be documented.

    in both the short and long term. The development of any neurological disorders (such as epilepsy) in the short or longer...

    Research recommendation
    Published
    9 June 2015

  44. Drug use disorders in adults (QS23)

    This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    19 November 2012
    View quality statements

    Sections for QS23

  45. Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

    Evidence-based recommendations on lenvatinib (Kisplyx) with pembrolizumab (Keytruda) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA858

  46. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

    NICE guideline
    Last updated
    7 November 2024
    View recommendations

    Sections for NG23

  47. Bedwetting in children and young people (QS70)

    This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 September 2014
    View quality statements

    Sections for QS70

  48. Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic...

    Research recommendation
    Published
    13 February 2019

  49. Further research is needed on the use and clinical utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be developed.

    utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be...

    Research recommendation
    Published
    9 June 2015

  50. Type 2 diabetes in adults. Patient decision aid on type 2 diabetes: agreeing my blood glucose (HbA1c) target

    What is the best blood glucose (HbA1c) target for me? Blood glucose and long-term health If you have type 2 diabetes you may have higher...